Pharmacogenomics of clopidogrel: Evidence and perspectives

Thrombosis Research

Volumn 128, Issue 4, 2011, Pages 307-316

  Yin, Tong ^a   Miyata, Toshiyuki ^b  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

Antiplatelet therapy; Clopidogrel; CYP2C19; Pharmacogenomics; PON1,P2Y 12 receptor

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; CLOPIDOGREL; CYTOCHROME P450 2C19;

ALLELE; DRUG ACTIVITY; DRUG FATALITY; DRUG LABELING; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; ETHNIC DIFFERENCE; FOOD AND DRUG ADMINISTRATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; LOADING DRUG DOSE; PHARMACODYNAMICS; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW; STENT THROMBOSIS; SYSTEMATIC REVIEW;

ARYL HYDROCARBON HYDROXYLASES; ARYLDIALKYLPHOSPHATASE; DRUG RESISTANCE; EVIDENCE-BASED MEDICINE; GENOTYPE; HUMANS; INDIVIDUALIZED MEDICINE; PATIENT SELECTION; PHARMACOGENETICS; PHENOTYPE; PLATELET AGGREGATION INHIBITORS; POLYMORPHISM, GENETIC; RISK ASSESSMENT; RISK FACTORS; TICLOPIDINE;

EID: 80053954075     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2011.04.010     Document Type: Review

References (79)

1. A.Y. Gasparyan, T. Watson, and G.Y. Lip The role of aspirin in cardiovascular prevention: implications of aspirin resistance J Am Coll Cardiol 51 2008 1829 1843 (Pubitemid 351615246)
2. S. Yusuf, F. Zhao, S.R. Mehta, S. Chrolavicius, G. Tognoni, and K.K. Fox Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation N Engl J Med 345 2001 494 502 (Pubitemid 32758501)
3. M.S. Sabatine, C.P. Cannon, C.M. Gibson, J.L. Lopez-Sendon, G. Montalescot, P. Theroux, B.S. Lewis, S.A. Murphy, C.H. McCabe, and E. Braunwald Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study Jama 294 2005 1224 1232 (Pubitemid 41352110)
4. M.S. Sabatine, C.P. Cannon, C.M. Gibson, J.L. Lopez-Sendon, G. Montalescot, P. Theroux, M.J. Claeys, F. Cools, K.A. Hill, A.M. Skene, C.H. McCabe, and E. Braunwald Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation N Engl J Med 352 2005 1179 1189 (Pubitemid 40397259)
5. Z.M. Chen, L.X. Jiang, Y.P. Chen, J.X. Xie, H.C. Pan, R. Peto, R. Collins, and L.S. Liu Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial Lancet 366 2005 1607 1621
6. D.L. Bhatt, M.E. Bertrand, P.B. Berger, P.L. L'Allier, I. Moussa, J.W. Moses, G. Dangas, M. Taniuchi, J.M. Lasala, D.R. Holmes, S.G. Ellis, and E.J. Topol Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting J Am Coll Cardiol 39 2002 9 14 (Pubitemid 34059855)
7. A.D. Michelson Antiplatelet therapies for the treatment of cardiovascular disease Nat Rev Drug Discov 9 2010 154 169
8. K. Kolandaivelu, and D.L. Bhatt Overcoming 'resistance' to antiplatelet therapy: targeting the issue of nonadherence Nat Rev Cardiol 7 2010 461 467
9. J.S. Paikin, J.W. Eikelboom, J.A. Cairns, and J. Hirsh New antithrombotic agents-insights from clinical trials Nat Rev Cardiol 7 2010 498 509
10. P.A. Gurbel, K.P. Bliden, B.L. Hiatt, and C.M. O'Connor Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity Circulation 107 2003 2908 2913 (Pubitemid 36736631)
11. T.A. Nguyen, J.G. Diodati, and C. Pharand Resistance to clopidogrel: a review of the evidence J Am Coll Cardiol 45 2005 1157 1164 (Pubitemid 40523131)
12. J.D. Snoep, M.M. Hovens, J.C. Eikenboom, J.G. van der Bom, J.W. Jukema, and M.V. Huisman Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis Am Heart J 154 2007 221 231 (Pubitemid 47069129)
13. A.R. Shuldiner, J.R. O'Connell, K.P. Bliden, A. Gandhi, K. Ryan, R.B. Horenstein, C.M. Damcott, R. Pakyz, U.S. Tantry, Q. Gibson, T.I. Pollin, W. Post, A. Parsa, B.D. Mitchell, N. Faraday, W. Herzog, and P.A. Gurbel Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy Jama 302 2009 849 857
14. S.D. Wiviott, and E.M. Antman Clopidogrel resistance: a new chapter in a fast-moving story Circulation 109 2004 3064 3067
15. D. Sibbing, O. von Beckerath, A. Schomig, A. Kastrati, and N. von Beckerath Impact of body mass index on platelet aggregation after administration of a high loading dose of 600 mg of clopidogrel before percutaneous coronary intervention Am J Cardiol 100 2007 203 205 (Pubitemid 47041981)
16. A. Singla, M.J. Antonino, K.P. Bliden, U.S. Tantry, and P.A. Gurbel The relation between platelet reactivity and glycemic control in diabetic patients with cardiovascular disease on maintenance aspirin and clopidogrel therapy Am Heart J 158 2009 784 e1-6
17. J.T. Brandt, S.L. Close, S.J. Iturria, C.D. Payne, N.A. Farid, C.S. Ernest 2nd, D.R. Lachno, D. Salazar, and K.J. Winters Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel J Thromb Haemost 5 2007 2429 2436 (Pubitemid 350154353)
18. K. Umemura, T. Furuta, and K. Kondo The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects J Thromb Haemost 6 2008 1439 1441 (Pubitemid 352016331)
19. J.L. Mega, S.L. Close, S.D. Wiviott, L. Shen, R.D. Hockett, J.T. Brandt, J.R. Walker, E.M. Antman, W. Macias, E. Braunwald, and M.S. Sabatine Cytochrome p-450 polymorphisms and response to clopidogrel N Engl J Med 360 2009 354 362
20. H.J. Bouman, E. Schomig, J.W. van Werkum, J. Velder, C.M. Hackeng, C. Hirschhauser, C. Waldmann, H.G. Schmalz, J.M. Ten Berg, and D. Taubert Paraoxonase-1 is a major determinant of clopidogrel efficacy Nat Med 17 2011 110 116
21. B. Giusti, A.M. Gori, R. Marcucci, C. Saracini, I. Sestini, R. Paniccia, P. Buonamici, D. Antoniucci, R. Abbate, and G.F. Gensini Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis Am J Cardiol 103 2009 806 811
22. D. Sibbing, J. Stegherr, W. Latz, W. Koch, J. Mehilli, K. Dorrler, T. Morath, A. Schomig, A. Kastrati, and N. von Beckerath Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention Eur Heart J 30 2009 916 922
23. T. Simon, C. Verstuyft, M. Mary-Krause, L. Quteineh, E. Drouet, N. Meneveau, P.G. Steg, J. Ferrieres, N. Danchin, and L. Becquemont Genetic determinants of response to clopidogrel and cardiovascular events N Engl J Med 360 2009 363 375
24. J.P. Collet, J.S. Hulot, A. Pena, E. Villard, J.B. Esteve, J. Silvain, L. Payot, D. Brugier, G. Cayla, F. Beygui, G. Bensimon, C. Funck-Brentano, and G. Montalescot Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study Lancet 373 2009 309 317
25. G. Paré, S.R. Mehta, S. Yusuf, S.S. Anand, S.J. Connolly, J. Hirsh, K. Simonsen, D.L. Bhatt, K.A. Fox, and J.W. Eikelboom Effects of CYP2C19 genotype on outcomes of clopidogrel treatment N Engl J Med 363 2010 1704 1714
26. D. Sibbing, W. Koch, D. Gebhard, T. Schuster, S. Braun, J. Stegherr, T. Morath, A. Schomig, N. von Beckerath, and A. Kastrati Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement Circulation 121 2010 512 518
27. G. Davi, and C. Patrono Platelet activation and atherothrombosis N Engl J Med 357 2007 2482 2494
28. C. Trumel, B. Payrastre, M. Plantavid, B. Hechler, C. Viala, P. Presek, E.A. Martinson, J.P. Cazenave, H. Chap, and C. Gachet A key role of adenosine diphosphate in the irreversible platelet aggregation induced by the PAR1-activating peptide through the late activation of phosphoinositide 3-kinase Blood 94 1999 4156 4165
29. U.R. Schwarz, J. Geiger, U. Walter, and M. Eigenthaler Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets-definition and detection of ticlopidine/clopidogrel effects Thromb Haemost 82 1999 1145 1152 (Pubitemid 29419734)
30. P. Savi, J.M. Pereillo, M.F. Uzabiaga, J. Combalbert, C. Picard, J.P. Maffrand, M. Pascal, and J.M. Herbert Identification and biological activity of the active metabolite of clopidogrel Thromb Haemost 84 2000 891 896
31. D. Woulfe, J. Yang, and L. Brass ADP and platelets: the end of the beginning J Clin Invest 107 2001 1503 1505 (Pubitemid 32574635)
32. B. Stein, V. Fuster, D.H. Israel, M. Cohen, L. Badimon, J.J. Badimon, and J.H. Chesebro Platelet inhibitor agents in cardiovascular disease: an update J Am Coll Cardiol 14 1989 813 836 (Pubitemid 19250565)
33. M. Kazui, Y. Nishiya, T. Ishizuka, K. Hagihara, N.A. Farid, O. Okazaki, T. Ikeda, and A. Kurihara Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite Drug Metab Dispos 38 2010 92 99
34. H. Caplain, F. Donat, C. Gaud, and J. Necciari Pharmacokinetics of clopidogrel Semin Thromb Hemost 25 Suppl 2 1999 25 28 (Pubitemid 29350288)
35. J.S. Hulot, A. Bura, E. Villard, M. Azizi, V. Remones, C. Goyenvalle, M. Aiach, P. Lechat, and P. Gaussem Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects Blood 108 2006 2244 2247 (Pubitemid 44497506)
36. Home Page of the Human Cytochrome P450 (CYP) Allele Nomenclature Committee Available from: http://www.cypalleles.ki.se/index.htm Mar. 7, 2011 Accessed
37. S.M. de Morais, G.R. Wilkinson, J. Blaisdell, K. Nakamura, U.A. Meyer, and J.A. Goldstein The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans J Biol Chem 269 1994 15419 15422
38. S.M. De Morais, G.R. Wilkinson, J. Blaisdell, U.A. Meyer, K. Nakamura, and J.A. Goldstein Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese Mol Pharmacol 46 1994 594 598 (Pubitemid 24334747)
39. S.C. Sim, C. Risinger, M.L. Dahl, E. Aklillu, M. Christensen, L. Bertilsson, and M. Ingelman-Sundberg A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants Clin Pharmacol Ther 79 2006 103 113 (Pubitemid 43069582)
40. R.J. Ferguson, S.M. De Morais, S. Benhamou, C. Bouchardy, J. Blaisdell, G. Ibeanu, G.R. Wilkinson, T.C. Sarich, J.M. Wright, P. Dayer, and J.A. Goldstein A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin J Pharmacol Exp Ther 284 1998 356 361 (Pubitemid 28109566)
41. Z.S. Xiao, J.A. Goldstein, H.G. Xie, J. Blaisdell, W. Wang, C.H. Jiang, F.X. Yan, N. He, S.L. Huang, Z.H. Xu, and H.H. Zhou Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele J Pharmacol Exp Ther 281 1997 604 609 (Pubitemid 27203121)
42. G.C. Ibeanu, J. Blaisdell, B.I. Ghanayem, C. Beyeler, S. Benhamou, C. Bouchardy, G.R. Wilkinson, P. Dayer, A.K. Daly, and J.A. Goldstein An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians Pharmacogenetics 8 1998 129 135 (Pubitemid 28227321)
43. G.C. Ibeanu, J. Blaisdell, R.J. Ferguson, B.I. Ghanayem, K. Brosen, S. Benhamou, C. Bouchardy, G.R. Wilkinson, P. Dayer, and J.A. Goldstein A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin J Pharmacol Exp Ther 290 1999 635 640 (Pubitemid 29344556)
44. J. Blaisdell, H. Mohrenweiser, J. Jackson, S. Ferguson, S. Coulter, B. Chanas, T. Xi, B. Ghanayem, and J.A. Goldstein Identification and functional characterization of new potentially defective alleles of human CYP2C19 Pharmacogenetics 12 2002 703 711 (Pubitemid 36054937)
45. I. Rudberg, B. Mohebi, M. Hermann, H. Refsum, and E. Molden Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients Clin Pharmacol Ther 83 2008 322 327
46. S.J. Lee, W.Y. Kim, H. Kim, J.H. Shon, S.S. Lee, and J.G. Shin Identification of new CYP2C19 variants exhibiting decreased enzyme activity in the metabolism of S-mephenytoin and omeprazole Drug Metab Dispos 37 2009 2262 2269
47. Z. Desta, X. Zhao, J.G. Shin, and D.A. Flockhart Clinical significance of the cytochrome P450 2C19 genetic polymorphism Clin Pharmacokinet 41 2002 913 958 (Pubitemid 35168437)
48. H.G. Xie, R.B. Kim, A.J. Wood, and C.M. Stein Molecular basis of ethnic differences in drug disposition and response Annu Rev Pharmacol Toxicol 41 2001 815 850 (Pubitemid 32385908)
49. P.J. Wedlund The CYP2C19 enzyme polymorphism Pharmacology 61 2000 174 183
50. P. Fontana, J.S. Hulot, P. De Moerloose, and P. Gaussem Influence of CYP2C19 and CYP3A4 gene polymorphisms on clopidogrel responsiveness in healthy subjects J Thromb Haemost 5 2007 2153 2155 (Pubitemid 47450038)
51. B. Giusti, A.M. Gori, R. Marcucci, C. Saracini, I. Sestini, R. Paniccia, S. Valente, D. Antoniucci, R. Abbate, and G.F. Gensini Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients Pharmacogenet Genomics 17 2007 1057 1064 (Pubitemid 351339490)
52. K.A. Kim, P.W. Park, S.J. Hong, and J.Y. Park The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance Clin Pharmacol Ther 84 2008 236 242
53. C. Frere, T. Cuisset, P.E. Morange, J. Quilici, L. Camoin-Jau, N. Saut, D. Faille, M. Lambert, I. Juhan-Vague, J.L. Bonnet, and M.C. Alessi Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome Am J Cardiol 101 2008 1088 1093
54. D. Trenk, W. Hochholzer, M.F. Fromm, L.E. Chialda, A. Pahl, C.M. Valina, C. Stratz, P. Schmiebusch, H.P. Bestehorn, H.J. Buttner, and F.J. Neumann Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents J Am Coll Cardiol 51 2008 1925 1934 (Pubitemid 351636443)
55. C. Frere, T. Cuisset, B. Gaborit, M.C. Alessi, and J.S. Hulot The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome J Thromb Haemost 7 2009 1409 1411
56. J.S. Hulot, J.P. Collet, J. Silvain, A. Pena, A. Bellemain-Appaix, O. Barthelemy, G. Cayla, F. Beygui, and G. Montalescot Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis J Am Coll Cardiol 56 2010 134 143
57. D.J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo, C. Ramirez, U. Cavallari, E. Trabetti, M. Sabate, R. Hernandez, R. Moreno, J. Escaned, F. Alfonso, C. Banuelos, M.A. Costa, T.A. Bass, P.F. Pignatti, and C. Macaya Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel Arterioscler Thromb Vasc Biol 26 2006 1895 1900 (Pubitemid 44305347)
58. K.A. Kim, P.W. Park, and J.Y. Park Effect of CYP3A5*3 genotype on the pharmacokinetics and antiplatelet effect of clopidogrel in healthy subjects Eur J Clin Pharmacol 64 2008 589 597
59. J.W. Suh, B.K. Koo, S.Y. Zhang, K.W. Park, J.Y. Cho, I.J. Jang, D.S. Lee, D.W. Sohn, M.M. Lee, and H.S. Kim Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel Cmaj 174 2006 1715 1722
60. S.M. Smith, H.M. Judge, G. Peters, M. Armstrong, P. Fontana, P. Gaussem, M.E. Daly, and R.F. Storey Common sequence variations in the P2Y12 and CYP3A5 genes do not explain the variability in the inhibitory effects of clopidogrel therapy Platelets 17 2006 250 258 (Pubitemid 43890796)
61. D.J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo, C. Ramirez, U. Cavallari, E. Trabetti, M. Sabate, P. Jimenez-Quevedo, R. Hernandez, R. Moreno, J. Escaned, F. Alfonso, C. Banuelos, M.A. Costa, T.A. Bass, P.F. Pignatti, and C. Macaya Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease Thromb Res 116 2005 491 497 (Pubitemid 41330814)
62. T. Cuisset, C. Frere, J. Quilici, P.E. Morange, N. Saut, M. Lambert, L. Camoin, I.J. Vague, J.L. Bonnet, and M.C. Alessi Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome Thromb Res 120 2007 893 899 (Pubitemid 47432706)
63. P. Fontana, A. Dupont, S. Gandrille, C. Bachelot-Loza, J.L. Reny, M. Aiach, and P. Gaussem Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects Circulation 108 2003 989 995 (Pubitemid 37048230)
64. D. Taubert, N. von Beckerath, G. Grimberg, A. Lazar, N. Jung, T. Goeser, A. Kastrati, A. Schomig, and E. Schomig Impact of P-glycoprotein on clopidogrel absorption Clin Pharmacol Ther 80 2006 486 501 (Pubitemid 44767878)
65. P.A. Gurbel, M.J. Antonino, and U.S. Tantry Recent developments in clopidogrel pharmacology and their relation to clinical outcomes Expert Opin Drug Metab Toxicol 5 2009 989 1004
66. D. Sibbing, N. von Beckerath, T. Morath, J. Stegherr, J. Mehilli, N. Sarafoff, S. Braun, S. Schulz, A. Schomig, and A. Kastrati Oral anticoagulation with coumarin derivatives and antiplatelet effects of clopidogrel Eur Heart J 31 2010 1205 1211
67. S.C. Khalique, and A. Cheng-Lai Drug interaction between clopidogrel and proton pump inhibitors Cardiol Rev 17 2009 198 200
68. Food and Drug Administration (clopidogrel) in patients who are poor metabolizers of the drug [safety announcement] Available at: www.fda.gov March 12, 2010 Accessed April 26, 2010
69. P.A. Gurbel, U.S. Tantry, A.R. Shuldiner, and D.J. Kereiakes Genotyping: one piece of the puzzle to personalize antiplatelet therapy J Am Coll Cardiol 56 2010 112 116
70. J. Shanker, A.Y. Gasparyan, G.D. Kitas, and V.V. Kakkar Platelet Function and Antiplatelet Therapy in Cardiovascular Disease: Implications of Genetic Polymorphisms Curr Vasc Pharmacol Feb. 14 2011 doi:BSP/CVP/E-Pub/0000138 [pii] [Epub ahead of print]
71. I. Muller, M. Seyfarth, S. Rudiger, B. Wolf, G. Pogatsa-Murray, A. Schomig, and M. Gawaz Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement Heart 85 2001 92 93 (Pubitemid 32973418)
72. D.J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo, C. Ramirez, M. Sabate, C. Banuelos, R. Hernandez-Antolin, J. Escaned, R. Moreno, F. Alfonso, and C. Macaya High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability Eur Heart J 25 2004 1903 1910 (Pubitemid 39452607)
73. J.L. Mega, S.L. Close, S.D. Wiviott, L. Shen, R.D. Hockett, J.T. Brandt, J.R. Walker, E.M. Antman, W.L. Macias, E. Braunwald, and M.S. Sabatine Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes Circulation 119 2009 2553 2560
74. M. Cattaneo New P2Y(12) inhibitors Circulation 121 2010 171 179
75. P.A. Gurbel, K.P. Bliden, K. Butler, M.J. Antonino, C. Wei, R. Teng, L. Rasmussen, R.F. Storey, T. Nielsen, J.W. Eikelboom, G. Sabe-Affaki, S. Husted, D.J. Kereiakes, D. Henderson, D.V. Patel, and U.S. Tantry Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study Circulation 121 2010 1188 1199
76. P.A. Gurbel, K.P. Bliden, M.J. Antonino, G. Stephens, D.D. Gretler, M.M. Jurek, R.E. Pakyz, A.R. Shuldiner, P.B. Conley, and U.S. Tantry The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients J Thromb Haemost 8 2010 43 53
77. C. Gensch, U. Hoppe, M. Bohm, and U. Laufs Late-breaking clinical trials presented at the American Heart Association Congress in Chicago 2010 Clin Res Cardiol 100 2010 1 9
78. K.M. Momary, M.P. Dorsch, and E.R. Bates Genetic causes of clopidogrel nonresponsiveness: which ones really count? Pharmacotherapy 30 2010 265 274
79. T.K. Ma, Y.Y. Lam, V.P. Tan, and B.P. Yan Variability in response to clopidogrel: how important are pharmacogenetics and drug interactions? Br J Clin Pharmacol 72 2011 697 706